VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice
- 1 March 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (3) , 984-93
- https://doi.org/10.1128/aac.50.3.984-993.2006
Abstract
Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.Keywords
This publication has 44 references indexed in Scilit:
- Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino OligomersPLoS Pathogens, 2006
- The Ebola Virus Genomic Replication Promoter Is Bipartite and Follows the Rule of SixJournal of Virology, 2005
- The evolving field of biodefence: therapeutic developments and diagnosticsNature Reviews Drug Discovery, 2005
- Rescue of Ebola virus from cDNA using heterologous support proteinsVirus Research, 2004
- Ebola virus: new insights into disease aetiopathology and possible therapeutic interventionsExpert Reviews in Molecular Medicine, 2004
- Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus InfectionThe Journal of Experimental Medicine, 2004
- Marburg virus-like particles protect guinea pigs from lethal Marburg virus infectionVaccine, 2004
- Cellular Uptake of Antisense Morpholino Oligomers Conjugated to Arginine-Rich PeptidesBioconjugate Chemistry, 2004
- Biochemical and Functional Characterization of the Ebola Virus VP24 Protein: Implications for a Role in Virus Assembly and BuddingJournal of Virology, 2003
- Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virusVirus Research, 1993